“The microbiome is a field of strong research interest with the potential to fundamentally change our understanding of living systems. It has substantial implications for medicine, agriculture and other areas. Abundance analysis of the microbiome is one key element of this research and Perseus’ innovative optical technology has the potential to enable it at a new level. The investment is a way of consistently implementing our strategy in the field of Advanced Sensor and Data Solutions,” Gerrit Schulte, Head of Zeiss Ventures, said in a company news release.
“We are pleased to announce this Partnership with Zeiss, and we see it as a formidable opportunity to accelerate the development and launch of Perseus MAP platform and establish it as a pioneer in the field of microbiome abundance mapping,” Walid N. Hanna, Executive Chairman of Perseus, said in the news release. “We have assembled a first class scientific and R&D team that ambitions to revolutionize microbiome analysis, making it faster, more precise and more affordable, while opening the way for broad reach personalized medicine. Access to Zeiss technology expertise in optics and its global market reach will be critical in the success of Perseus.”